Internal Medicine, Medical Oncology · Mobile, AL
NPI
1881805406
Since 2007
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3719 Dauphin St Fl 5
Mobile, AL, 36608
Phone (251) 625-6896
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.3M
137,934 services
Medicare patients, 2024
464
Average age 74
Drug cost, 2024
$6.4M
2,811 prescriptions
Company payments, 2025
$3,265
From 43 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sherri S Arledge was code J1453 (injection, fosaprepitant, 1 mg), 15,300 times for 18 patients. In total Sherri S Arledge billed 137,934 services in 147 codes, and Medicare paid $2.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1453 Injection, fosaprepitant, 1 mg | Office | 15,300 | 18 | $0.11 | $1,733 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 11,400 | 14 | $44.74 | $510K |
| J0897 Injection, denosumab, 1 mg | Office | 2,820 | 16 | $20.54 | $58K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 2,152 | 19 | $0.07 | $158 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,004 | 33 | $0.09 | $180 |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 1,836 | 11 | $5.75 | $11K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,440 | 22 | $0.68 | $984 |
| 99214 Office E&M - Established | Office | 786 | 305 | $87.00 | $68K |
| 36415 Venipuncture Blood Collection | Office | 785 | 269 | $8.65 | $6,790 |
| 85025 Blood Count | Office | 766 | 268 | $7.55 | $5,780 |
| Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 732 | 18 | $112.12 | $82K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 644 | 273 | $12.16 | $7,828 |
| 80053 Clinical Chemistry | Office | 591 | 230 | $10.26 | $6,063 |
| 96367 Intravenous Infusion, Hydration | Office | 533 | 49 | $19.58 | $10K |
| 96372 Injection Administration | Office | 412 | 76 | $9.69 | $3,991 |
By year: 2022 $2.7M for 120,656 services; 2023 $2.1M for 136,686 services; 2024 $2.3M for 137,934 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 785 | 269 | $8.65 | $6,790 |
| 85025 Blood Count | 766 | 268 | $7.55 | $5,780 |
| 80053 Clinical Chemistry | 591 | 230 | $10.26 | $6,063 |
| 82728 Clinical Chemistry | 126 | 82 | $13.07 | $1,647 |
| 83521 Immunoassay | 120 | 29 | $16.40 | $1,968 |
| 83540 Clinical Chemistry | 111 | 75 | $6.26 | $694 |
| 83550 Clinical Chemistry | 104 | 71 | $8.40 | $873 |
| 86300 Immunoassay | 88 | 49 | $20.39 | $1,794 |
| 81003 Clinical Chemistry | 75 | 15 | $2.20 | $165 |
| 83615 Clinical Chemistry | 59 | 35 | $5.92 | $349 |
Medicare prescription drug claims, 2024
In 2024, the drug Sherri S Arledge prescribed most often to Medicare patients was Letrozole, with 376 prescriptions and refills. In total Sherri S Arledge wrote 2,811 Medicare prescriptions that cost $6.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 376 | 872 | 103 | $9,478 |
| Ondansetron Hcl Generic | 146 | 146 | 85 | $2,519 |
| Anastrozole Generic | 121 | 324 | 43 | $2,696 |
| Prochlorperazine Maleate Generic | 105 | 105 | 63 | $2,237 |
| Acyclovir Generic | 102 | 136 | 21 | $1,426 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 92 | 92 | 36 | $2,328 |
| Potassium Chloride Generic | 77 | 121 | 31 | $1,280 |
| Tamoxifen Citrate Generic | 74 | 166 | 19 | $2,026 |
| Hydroxyurea Generic | 69 | 126 | 16 | $1,574 |
| Dexamethasone Generic | 66 | 75 | 20 | $1,464 |
| Promethazine Hcl Generic | 60 | 60 | 17 | $680 |
| Gabapentin Generic | 49 | 57 | 19 | $649 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 48 | 51 | 37 | $665 |
| Lenalidomide Generic | 48 | 48 | Under 11 | $636K |
| Jakafi Ruxolitinib Phosphate | 48 | 48 | Under 11 | $681K |
Brand drugs: 522 claims; generic drugs: 2,289 claims; opioid claims: 241.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sherri S Arledge $3,265 ($3,265 in general payments such as food, travel and fees) from 43 companies. The largest payer was Novartis Pharmaceuticals Corporation with $292.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 14 | $292 |
| Daiichi Sankyo Inc. 4568.T | 9 | $219 |
| Celgene Corporation BMY | 8 | $216 |
| Alexion Pharmaceuticals, Inc. AZN | 3 | $207 |
| Merck Sharp & Dohme LLC MRK | 7 | $163 |
| Janssen Biotech, Inc. JNJ | 9 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $145 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $144 |
| Pfizer Inc. PFE | 7 | $118 |
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $111 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.